Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Erectile Dysfunction Drugs May Prevent Colon Cancer

By Drug Discovery Trends Editor | October 3, 2013

GRU Graduate Student Rui Wang (left) and Dr. Darren Browning, Cancer Researcher. (Source: Georgia Regents University)Erectile dysfunction drugs may be able to help prevent or even treat colon cancer, researchers say.
 
They are studying three drugs, including Viagra, that appear to protect the lining of the colon from inflammation and other damage resulting from the relentless onslaught of food, drink and bacteria that we consume. They say the drugs work by protecting the integrity of the colon’s natural barrier and reducing excessive and risky cell proliferation.
 
“We’ve found a way of activating a tumor suppressive pathway in the gut using drugs already in use for erectile dysfunction,” said Dr. Darren Browning, cancer researcher at the Georgia Regents University Cancer Center and a faculty member at the Medical College of Georgia.
 
Browning just received a $1.8 million National Cancer Institute grant to further explore how and how well the drugs work to prevent colon cancer.
 
As with most things, a healthy colon is about balance, in this case tight regulation of the process of cells dying and new cells forming and differentiating in the dynamic, caustic environment. “It’s basically the inside of your body exposed to the outside world,” Browning said of the colon, or large intestines.
 
The colon is lined with a sheet of mucus on top of a single layer of tightly knit epithelial cells that is peppered with tiny pits, or crypts. To deal with the naturally high turnover of cells in this tough environment, the crypts hold stem cells which produce proliferating cells that ultimately rise up and differentiate into new cells to help maintain important functions such as mucus production and nutrient absorption. Mucus reciprocates by continually oozing out of the crypts to keep foreign object from venturing inside.  
 
“They replace the whole lining every few days,” Browning said. If the renewal process gets out of balance, the protective barrier of mucus and endothelial cells can break down, exposing underlying tissue to gut contents, causing inflammation and setting the stage for cancer. 
 
Browning had discovered that an enzyme called type 2 protein kinase G, or PKG2, has an important role in protecting the cells that make up the barrier and slowing down cell proliferation in the colon. His research team set about looking for ways to increase PKG activation in the colon as a way to reduce cancer risk and help patients with inflammatory bowel disease.
 
“We became interested in the erectile dysfunction drugs because they are known to increase the levels of a chemical called cyclicGMP, which can activate PKG,” Browning said.
 
In the penis, the drugs’ activation of PKG relaxes the smooth, circular muscles around blood vessels so they can fill with blood. The drugs essentially work the same way to reduce pulmonary hypertension in premature babies. 
 
The three drugs Browning is using in the colon inhibit phosphodiesterase, an enzyme that breaks bonds, in this case, cleaving cyclicGMP so that it does essentially nothing. Inside the colon, Browning found that the drugs activate PKG2.
 
He has two mouse models, one with a genetic predisposition for colon cancer and another with a more common, inflammation-driven disease. They’ll be giving the drugs by mouth to both models to see if they can prevent or dramatically reduce the incidence of colon cancer.  They also want to know which drug works best and to double check that PKG2 is a central point of action that results in barrier protection and cancer prevention.
 
Browning also is pursing the drugs’ effectiveness in colitis, a painful inflammation of the colon and a major risk factor for colon cancer, in which the balance of cell death and differentiation also is lost.
 
“If the drugs continue to work as our studies to date have indicated, the next stage is clinical trials because these drugs are in the clinic already,” Browning said.
 
Date: October 2, 2013
Source: Georgia Regents University

Filed Under: Drug Discovery

 

Related Articles Read More >

SAS launches clinical trial analytics software built on its Viya cloud native analytics platform
Bayer’s Lynkuet approved by FDA for menopausal hot flashes
How stereo-correct data can de-risk AI-driven drug discovery
eConsent as the digital foundation for modern clinical trials 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE